Skip to main content
Download PDF

Co-infection and enterovirus B: post EV-A71 mass vaccination scenario in China

BMC Infectious Diseases volume 22, Article number: 671 (2022) Cite this article

Abstract

Background

Hand, foot, and mouth disease (HFMD) is a common child infectious disease caused by more than 20 enterovirus (EV) serotypes. In recent years, enterovirus A71 (EV-A71) has been replaced by Coxsackievirus A6 (CV-A6) to become the predominant serotype. Multiple EV serotypes co-circulate in HFMD epidemics, and this study aimed to investigate the etiological epidemic characteristics of an HFMD outbreak in Kunming, China in 2019.

Methods

The clinical samples of 459 EV-associated HFMD patients in 2019 were used to amplify the VP1 gene region by the three sets of primers and identify serotypes using the molecular biology method. Phylogenetic analyses were performed based on the VP1 gene.

Results

Three hundred and forty-eight cases out of 459 HFMD patients were confirmed as EV infection. Of these 191 (41.61%) were single EV infections and 34.20% had co-infections. The EVs were assigned to 18 EV serotypes, of which CV-A6 was predominant (11.33%), followed by CV-B1 (8.93%), CV-A4 (5.23%), CV-A9 (4.58%), CV-A 16 (3.49%) and CV-A10 and CVA5 both 1.96%. Co-infection of CV-A6 with other EVs was present in 15.25% of these cases, followed by co-infection with CV-A16 and other EVs. The VP1 sequences used in the phylogenetic analyses showed that the CV-A6, CV-B1 and CV-A4 sequences belonged to the sub-genogroup D3 and genogroups F and E, respectively.

Conclusion

Co-circulation and co-infection of multiple serotypes were the etiological characteristic of the HFMD epidemic in Kunming China in 2019 with CV-A-6, CV-B1 and CV-A4 as the predominant serotypes. This is the first report of CV-B1 as a predominant serotype in China and may provide valuable information for the diagnosis, prevention and control of HFMD.

Peer Review reports

Background

The genus Enterovirus (EVs) are categorized into fifteen species including EV-A, B, C, D, E, F, G, H, I, J, K and L and Rhinovirus A, B and C within the family Picornaviridae, including 274 serotypes (www.picornaviridae.com/sg3_ensavirinae/enterovirus/enterovirus.htm). Since 2008, hand, foot and mouth disease (HFMD) has been a common children’s disease in China, caused by EV-A, EV-B, and EV-C [1]. The disease is characterized by fever and vesicular eruptions on the hands, feet and oral mucosa, but some patients can develop severe complications including encephalitis, meningitis, brainstem encephalitis, acute flaccid paralysis, cardiorespiratory failure and death [2, 3]. Although China has had access to an EV-A71 vaccine since 2016, the incidence of HFMD is still extremely high [4]. Currently Coxsackieviruses (CV)-A6 and -A10 have become the predominant serotypes, causing mild, severe and fatal cases of HFMD [4]. Co-circulation of multi-serotypes has become an epidemiological feature of FHMD outbreaks [4, 5], but the serotypes have no cross protection. To fully control HFMD caused by multiple serotypes, a multivalent vaccine needs to be developed. Epidemic and pathogen surveillance can provide valuable information on measures to prevent and control HFMD and on the formulation of multivalent vaccines.

The purpose of this study was to investigate the etiology spectrum after mass vaccination using an EV-A71 vaccine, combining three sets of primers to analyze the etiological characteristics of EVs in HFMD specimens. By analyzing the prevalence of pathogens, changes in the etiological spectrum can be monitored and strategies provided for developing multivalent vaccines to prevent HFMD.

Methods

Patients and clinical sample collection

Kunming City is a tourist city in the southwest region of China, covering an area of 21,473 km [2] and has a population of 6,950,000. The annual average temperature is 15 °C. A total of 459 stool specimens from children admitted with HFMD were collected in 2019, when the data of the patient’s personal details and clinical symptoms was collected, and the stool specimens obtained were stored at − 80 °C. The clinical and laboratory diagnoses of cases were based on the diagnostic criteria in the Guidelines for the Diagnosis and Treatment of HFMD 2018 edition (China) [6].

Nucleotide acid detection by real time polymerase chain reaction (RT–PCR)

Viral RNAs were extracted using with a QIAamp Viral RNA Mini Kit (Qiagen, Valencia, CA, USA). The detection of pan-enteroviruses, EV-A71, CV-A16, CV-A6, and CV-A10 was performed in the Applied Biosystems-7500 system by one-step RT–PCR assay (Daan Biotech, Guangzhou, China). The RT-PCR was conducted based on the standard protocol as 50 °C for 30 min, 95 °C for 5 min and then followed by 45 cycles with 95 °C at 10 s and 55 °C at 40 s. Samples with a CT (Cycle Threshold) value less than 43 were considered positive.

Amplification of the partial VP1 regions and sequencing

To further identify the serotypes according to the standard protocol, three half-nested and nested primers are used to amplify the VP1 gene region of a specimen [7,8,9]. One gram of stool specimen was suspended in 5 mL of phosphate buffered saline (PBS) and the suspension was centrifuged at 4 °C, 2000×g for 30 min. According to the manufacturer’s recommended procedure, a QIAamp Viral RNA Mini Kit (Qiagen, Valencia, CA, USA) was used to extract viral RNA. Reverse transcription polymerase chain reaction (RT-PCR) and PCR were conducted using a PrimeScript One-Step RT-PCR kit ver.2 (Takara, China) and Pyrobest™ DNA Polymerase (TaKaRa, China). The first round of RT-PCR was performed in a 25 µL reaction containing 8 µL RNA, 1 µL RT-PCR mix (Takara, China), 12.5 µL of 2× reaction buffer, and 20 pmol each of the outer primers for EV-A or EV-B or 222 and 224. The amplification program was 50 °C for 30 min, 94 °C for 2 min, followed by 30 cycles of 94 °C for 30 s, 52 °C for 30 s and 72 °C for 1 min. The second round of PCR was performed with 5 µL of the first-round PCR products and 20 pmol of each of the inner primers in a volume of 25 µL under the same PCR conditions described above. The positive PCR products were purified and bidirectionally sequenced on an ABI3730XL automatic sequencer (Applied Biosystems, Foster City, CA, USA). The obtained sequences were used for molecular typing with the online Enterovirus Genotyping Tool version 0.1.

Sequence analysis and phylogenetic analysis

Multiple partial VP1 sequences were aligned at BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi). Geneious 5.4.1 software was used for nucleotide sequence alignment and homology comparison. The phylogenetic analysis based on the VP1 sequence was conducted in the MEGA 6 program, using the neighbor-joining method (NJ) and the maximum comprehensive likelihood method as well as the Kimura two-parameter model [6]. A Bootstrap value exceeding 75% was considered statistically significant. A nucleotide difference of more than 15% between groups in the VP1 region was used to distinguish genotypes.

Statistical analysis

The data were analyzed using the SPSS 26.0 statistical software (SSPS, Inc, Chicago, IL). Data were analyzed by a one-way analysis of variance test. P < 0.05 were considered statistically significant.

Nucleotide sequence accession number

The VP1 sequences of the EV strains obtained in this study were deposited in the GenBank database under the accession numbers: OK315571-OK315637.

Results

Cases and epidemiology

A total of 459 cases of HFMD were reported during the study period and 348 (75.82%) were positive for EVs. The sex ratio was 1.40:1, with 268 patients as boys and 191 were girls. The average age of the patients (± SD) is 2.8 (± 1.90) years. And all patients in the study previously were not vaccinated with the EV-A71 vaccine.

Pathogenic characteristics

Cases of infection due to EV were 348 (75.82%) of which 191 (41.61%) were a single EV infection and detected EVs belonged to 18 EV serotypes. Of these, CV-A6 was predominant, accounting for 11.33% of the cases, followed by CV-B1 (8.93%), CV-A4 (5.23%), CV-A9 (4.58%), CV-A16 (3.49%) and CV-A10 and CV-A5, both 1.96%.

Co-infection accounted for 34.20% of cases. Except for EV-A71 and CV-A16, the co-infection of CV-A6 and other EVs dominates (15.25%), followed by the co-infection of CV-A16 and other EVs (10.02%, except for EV-A71 and CV-A6), and co-infection of other EVs (5.01%). In severe cases, co-infection of CV-A16 and other EVs dominates, followed by co-infection of CV-A6 and other EVs, except for EV-A71 and CV-A16) co-infection of EV-A71 and other EVs, except Co-infection of CV-A6 and CV-A16 and other EVs (Table 1).

Table 1 The pathogens identified in patients with hand-foot-mouth disease in Yunnan, China, 2019
Full size table

Phylogenetic analysis

The CV-A6 genotypes A, B, C and D were identified and B and C genotypes were further divided into sub-genotypes B1 and 2, and C1 and 2, respectively. Sixty-three sequences, made up of 28 strains from this study and 35 from the GenBank were randomly selected to construct a phylogenetic tree. This showed that CV-A6 isolates in the study belonged to genotype D3 (Fig. 1), which belonged to the predominant strain in mainland China. The nucleotide and amino acid similarities of the partial VP1 gene between the CV-A6 isolates in the study and other Chinese CV-A6 strains were 83.5–95.4% and 94.7–98.9%, respectively.

The CV-B1 strains were divided into A, B, C, D, E and F genotypes, respectively. A phylogenetic tree was constructed from 29 partial VP1 nucleotide sequences that were randomly selected from those of this study and 39 representative strains from GenBank (Fig. 1). All the isolates from this study were of genotype F, which belonged to the main Chinese predominant strains. The nucleotide and amino acid similarities of the partial VP1 gene between the CV-B1 isolates in this study and other Chinese CV-B1 strains within the VP1 gene were 81.3–95.6% and 97.1–100%, respectively.

Fig. 1
figure 1

Phylogenetic trees of coxsackievirus B1, coxsackievirus A6, and coxsackievirus A4 based on the partial VP1 sequences by the neighbor-joining algorithm implemented in MEGA (version 7.0) using the Kimura two-parameter substitution model and 1000 bootstrap pseudo-replicates, respectively. Only strong bootstrap values (> 75%) are shown. ● Indicates strains isolated in this investigation; ▲ indicates the prototype strain

Full size image

The phylogenetic analysis of 24 CV-A4 strains in the study and 34 the representative strains (Fig. 1) found that CV-A4 strains were divided into A, B, C, D, and E genotypes. The isolates in the study were part of the E strain, which also belonged to the main Chinese predominant strains. The nucleotide and amino acid similarities of the partial VP1 gene between the CV-A6 isolates in the study and other Chinese CV-A6 strains were 86.0–96.5% and 97.6–98.8%, respectively.

Discussion

Currently, more than 20 enterovirus serotypes have been associated with HFMD in China and have often co-circulated in outbreaks or in sporadic infection [5, 10]. Most of them are usually detected at low proportions, with EV-A71 decreasing dramatically and CV-A16 still one of the main causative agents. Other EVs such as CV-A6 and CV-A10 are now the main causative agents of HFMD [4, 11], with CV-A4 also frequently detected in HFMD outbreaks [12,13,14].

This study is the first to report a new HFMD epidemic pattern characterized by co-circulation of three main EV serotypes CV-A6, CV-A4, and CV-B1 in Kunming, with the ratio of co-infection of multiple serotypes significantly higher, which was not consistent with previous reports [4, 5, 10]. In Kunming, EV-A71 and CV-A16 were the main causative agents of HFMD from 2009 to 2015, EV-A71 was the main causative agent in 2009, 2011, 2013, and 2015, but in 2010, 2012 and 2014, CV-A16 was the main causative agent [15]. In 2018, CV-A6, CV-A10 and CV-A16 were the main causative agents [4]. In 2019, CV-A-6, CV-A4, and CV-B1 were the main causative agents and co-circulated in the HFMD outbreak in Kunming. Though EV-A71 had been often associated with severe or fatal cases [4, 12], EV-A71-positive cases have decreased dramatically and led to a significant reduction in the severity and death rate [4, 11]. This reduction in the incidence of EV-A71 may be due to the successful use of the EV-A71 vaccine [16, 17], but the proportion of severe HFMD is still much higher, so even if the number of EV-A71 positive cases is small, monitoring of these cases is still important.

This study also found that CV-A6, CV-A10, CV-A16 and CV-A4 were associated with severe HFMD cases, which was consistent with previous reports [12]. Other EVs such as CV-B1, CV-A9, CV-A5 and E18 were also associated with severe HFMD cases in this study. The ratio of severe HFMD caused by CV-B1, CV-A9 and E-18 was much larger in the group of severe HFMD cases, as was the ratio of multiple serotypes co-infection. In addition, the proportion of co-infection with multiple serotypes is very much higher in the study, which is consistent with previous report [18]. And this pattern of infection might contribute significantly to the clinicopathological progression, thereby influence the incidence and symptoms of the disease [18,19,20,21].

Recombination frequently occurs for EVs [22, 23]and several of the current predominant strains have been confirmed as recombinant strains [24,25,26,27]. This recombination may occur due to the favorable simultaneous co-infection and replication of the different viruses in the same cell [27]. Although EV-A71 vaccine has been introduced into China, the number of HFMD cases is still very high. The multi-serotypes co-circulate and co-infect simultaneously, and one EV serotype lacks cross immunity protection for patients infected with other serotypes, which may be the reasons that HFMD continues to cause epidemics and outbreaks. This epidemiological feature not only poses a challenge for diagnosis, but also for the prevention and control of HFMD. It is therefore very important to detect more EV serotypes including EV-B for HFMD and the development of multivalent vaccines will be helpful to decrease the morbidity associated with HFMD.

More importantly, the EV-B serotypes are often not the preferred serotype to try to detect in HFMD epidemics. This study found that EV-Bs accounted for 37.70% in the single EV infection HFMD cases, consisting of CV-B1 (21.47%) and CV-A9 (10.99%). In the HFMD outbreaks of Shandong, China in 2009, 17.4% were CV-B strains, 11.8% were CV-B4 and in 2011 [28], CV-B5, CV-A16 and EV-A71 were the three main serotypes [29]. In Korea from 2012 to 2019, a total of 45 EV types were detected from 4399 samples with EV-associated symptoms, with EV-A71 the most detected (15.8%), E-30 (10.0%), CV-B5 (7.8%), CV-A6 (7.6%) and CV-A10 (7.4%). Of these, 46.7% were EV-A and 52.0% were EV-B [30], which indicated EV-Bs were an underestimated pathogen.

Cases due to EV-Bs are mostly asymptomatic or mild, but a few may cause severe issues such as aseptic meningitis, encephalitis, acute myalgia and rhabdomyolysis, pancreatitis and myocarditis, acute flaccid paralysis (AFP) and other serious diseases. Of these, CV-B1 has associated with an increased risk of type 1 diabetes (T1D) and was the predominant EV among neonates in the United States in 2007 [31], with CV-B1 epidemics causing life-threatening neonatal infections [32, 33]. Since the outbreak of HFMD in 2008, CV-B1 was often detected in China [34,35,36] and CV-B1 accounted for 21.47% in the single EV infection HFMD cases in the study. This indicated the monitoring of CV-B1should be enhanced. Therefore, it is very important to detect more EV serotypes including EV-B for HFMD and the development of multivalent vaccines will be helpful to decrease the morbidity associated with HFMD.

Conclusion

From 459 HFMD patients in Kunming China in 2019, 18 EV serotypes were identified of which CV-A-6, CV-B1 and CV-A4 were the predominant serotypes. This study presented a comprehensive and detailed investigation regarding the outbreak of HFMD in Kunming based on the pathogenetic and phylogenetic analysis. This will be beneficial for the future prevention and control of HFMD.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

EV:

Enterovirus

HFMD:

Hand foot and mouth disease

EV71:

Human enterovirus 71

CV-A16:

Coxsackievirus A16

CV-A4:

Coxsackievirus A4

CV-A10:

Coxsackievirus A10

CV-B5:

Coxsackievirus B5

CV-B1:

Coxsackievirus B1

CV-A5:

Coxsackievirus A5

CV-A9:

Coxsackievirus A9

E18:

Echovirus 18

E30:

Echovirus 30

CV-A6:

Coxsackievirus A6

AFP:

Acute flaccid paralysis

T1D:

Type 1 diabetes

CT:

Cycle threshold

SD:

Standard deviation

References

  1. Wang Y, Cao Z, Zeng D, Wang X, Wang Q. Using deep learning to predict the hand-foot-and-mouth disease of enterovirus A71 subtype in Beijing from 2011 to 2018. Sci Rep. 2020;10(1):12201.

    Article  CAS  Google Scholar 

  2. Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9(11):1097–105.

    Article  Google Scholar 

  3. Long L, Xu L, Xiao Z, Hu S, Luo R, Wang H, Lu X, Xu Z, Yao X, Zhou L, et al. Neurological complications and risk factors of cardiopulmonary failure of EV-A71-related hand, foot and mouth disease. Sci Rep. 2016;6:23444.

    Article  CAS  Google Scholar 

  4. Jiang H, Zhang Z, Rao Q, Wang X, Wang M, Du T, Tang J, Long S, Zhang J, Luo J, et al. The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China. Emerg Microbes Infect. 2021;10(1):619–28.

    Article  CAS  Google Scholar 

  5. Du Z, Zhao Y, Luo Y, Du L, Gan Q, Zhang H, Li J, Yang Z, Ma S. Ongoing change of severe hand, foot, and mouth disease pathogens in Yunnan, China, 2012 to 2016. J Med Virol. 2019;91(5):881–5.

    Article  Google Scholar 

  6. Chinese Center for Disease Control and Prevention. Guide of prevention and control for hand, foot and mouth disease; 2009. http://www.chinacdc.cn/jkzt/crb/bl/szkb/jszl_2275/200906/t20090612_24707.html. Accessed 20 Mar 2020.

  7. Nix WA, Oberste MS, Pallansch MA. Sensitive, seminested PCR amplification of VP1 sequences for direct identification of all enterovirus serotypes from original clinical specimens. J Clin Microbiol. 2006;44(8):2698–704.

    Article  CAS  Google Scholar 

  8. Leitch EC, Harvala H, Robertson I, Ubillos I, Templeton K, Simmonds P. Direct identification of human enterovirus serotypes in cerebrospinal fluid by amplification and sequencing of the VP1 region. J Clin Virol. 2009;44(2):119–24.

    Article  Google Scholar 

  9. Iturriza-Gomara M, Megson B, Gray J. Molecular detection and characterization of human enteroviruses directly from clinical samples using RT-PCR and DNA sequencing. J Med Virol. 2006;78(2):243–53.

    Article  CAS  Google Scholar 

  10. Ai Y, Zhang W, Wu J, Zhang J, Shen M, Yao S, Deng C, Li X, Wu D, Tian P, et al. Molecular epidemiology and clinical features of enteroviruses-associated hand, foot, and mouth disease and herpangina outbreak in Zunyi, China, 2019. Front Med (Lausanne). 2021;8:656699.

    Article  Google Scholar 

  11. Wang J, Jiang L, Zhang C, He W, Tan Y, Ning C. The changes in the epidemiology of hand, foot, and mouth disease after the introduction of the EV-A71 vaccine. Vaccine. 2021;39(25):3319–23.

    Article  CAS  Google Scholar 

  12. Zhao Y, Zhang H, Liu H, Zhang J, He L, Sun H, Huang X, Yang Z, Ma S. Molecular characteristics of hand, foot, and mouth disease for hospitalized pediatric patients in Yunnan, China. Medicine (Baltimore). 2018;97(31):e11610.

    Article  CAS  Google Scholar 

  13. Thammasonthijarern N, Kosoltanapiwat N, Nuprasert W, Sittikul P, Sriburin P, Pan-Ngum W, Maneekan P, Hataiyusuk S, Hattasingh W, Thaipadungpanit J, et al. Molecular epidemiological study of hand, foot, and mouth disease in a kindergarten-based setting in Bangkok, Thailand. Pathogens. 2021;10(5):576.

    Article  CAS  Google Scholar 

  14. Song C, Li Y, Zhou Y, Liang L, Turtle L, Wang F, Wu P, Qiu Q, Yang J, Wang K, et al. Enterovirus genomic load and disease severity among children hospitalised with hand, foot and mouth disease. EBioMedicine. 2020;62:103078.

    Article  CAS  Google Scholar 

  15. Jiang L, Jiang H, Tian X, Xia X, Huang T. Epidemiological characteristics of hand, foot, and mouth disease in Yunnan Province, China, 2008–2019. BMC Infect Dis. 2021;21(1):751.

    Article  Google Scholar 

  16. Takahashi S, Liao Q, Van Boeckel TP, Xing W, Sun J, Hsiao VY, Metcalf CJ, Chang Z, Liu F, Zhang J, et al. Hand, foot, and mouth disease in China: modeling epidemic dynamics of enterovirus serotypes and implications for vaccination. PLoS Med. 2016;13(2):e1001958.

    Article  Google Scholar 

  17. Fu X, Wan Z, Li Y, Hu Y, Jin X, Zhang C. National epidemiology and evolutionary history of four hand, foot and mouth disease-related enteroviruses in China from 2008 to 2016. Virol Sin. 2020;35(1):21–33.

    Article  CAS  Google Scholar 

  18. Ma S, Du Z, Feng M, Che Y, Li Q. A severe case of co-infection with Enterovirus 71 and vaccine-derived Poliovirus type II. J Clin Virol. 2015;72:25–9.

    Article  Google Scholar 

  19. Ma S, Zhang Y, Du C, Yang T, Liu Q, Pan Y, Chen J, Shi H, Sun Q, Liu L, et al. Dynamic constitution of the pathogens inducing encephalitis in hand, foot and mouth disease in Kunming, 2009–2011. Jpn J Infect Dis. 2015;68(6):504–10.

    Article  CAS  Google Scholar 

  20. Yang F, Du J, Hu Y, Wang X, Xue Y, Dong J, Sun L, Li Z, Li Y, Sun S, et al. Enterovirus coinfection during an outbreak of hand, foot, and mouth disease in Shandong, China. Clin Infect Dis. 2011;53(4):400–1.

    Article  Google Scholar 

  21. Han JF, Zhang Y, Hou PQ, Zhu SY, Wu XY, Zhao H, Yu M, Qin CF. Human enterovirus co-infection in severe HFMD patients in China. J Clin Virol. 2014;61(4):621–2.

    Article  Google Scholar 

  22. Zhang J, Zhang H, Zhao Y, Guo C, Yang Z, Ma S. Molecular characterization of a new human coxsackievirus B2 associated with severe hand-foot-mouth disease in Yunnan Province of China in 2012. Arch Virol. 2017;162(1):307–11.

    Article  CAS  Google Scholar 

  23. Zheng H, Zhang Y, Liu L, Lu J, Guo X, Li H, Zeng H, Fang L, Xu W, Ke C. Isolation and characterization of a highly mutated Chinese isolate of enterovirus B84 from a patient with acute flaccid paralysis. Sci Rep. 2016;6:31059.

    Article  CAS  Google Scholar 

  24. Zhou J, Shi Y, Miao L, Zhang C, Liu Y. Molecular epidemiology and recombination of enterovirus A71 in mainland China from 1987 to 2017. Int Microbiol. 2021;24(3):291–9.

    Article  CAS  Google Scholar 

  25. Yu F, Zhu R, Jia L, Song Q, Deng J, Liu L, Zhao L, Qian Y. Sub-genotype change and recombination of coxsackievirus A6s may be the cause of it being the predominant pathogen for HFMD in children in Beijing, as revealed by analysis of complete genome sequences. Int J Infect Dis. 2020;99:156–62.

    Article  CAS  Google Scholar 

  26. Brown DM, Zhang Y, Scheuermann RH. Epidemiology and sequence-based evolutionary analysis of circulating non-polio enteroviruses. Microorganisms. 2020;8(12):1856.

    Article  CAS  Google Scholar 

  27. Muslin C, Mac Kain A, Bessaud M, Blondel B, Delpeyroux F. Recombination in enteroviruses, a multi-step modular evolutionary process. Viruses. 2019;11(9):859.

    Article  CAS  Google Scholar 

  28. Xiao J, Wang J, Zhang Y, Sun D, Lu H, Han Z, Song Y, Yan D, Zhu S, Pei Y, et al. Coxsackievirus B4: an underestimated pathogen associated with a hand, foot, and mouth disease outbreak. Arch Virol. 2021;166(8):2225–34.

    Article  CAS  Google Scholar 

  29. Hu YF, Yang F, Du J, Zhang T, Xue Y, Jin Q. Coxsackievirus B5, associated with neurological hand, foot and mouth disease, China. J Infect. 2012;65(2):189–91.

    Article  CAS  Google Scholar 

  30. Kang HJ, Yoon Y, Lee YP, Kim HJ, Lee DY, Lee JW, Hyeon JY, Yoo JS, Lee S, Kang C, et al. A different epidemiology of enterovirus A and enterovirus B co-circulating in Korea, 2012–2019. J Pediatr Infect Dis Soc. 2021;10(4):398–407.

    Article  CAS  Google Scholar 

  31. Centers for Disease Control and Prevention. Increased detections and severe neonatal disease associated with coxsackievirus B1 infection–United States, 2007. MMWR Morb Mortal Wkly Rep. 2008;57(20):553–6.

    Google Scholar 

  32. Wikswo ME, Khetsuriani N, Fowlkes AL, Zheng X, Penaranda S, Verma N, Shulman ST, Sircar K, Robinson CC, Schmidt T, et al. Increased activity of Coxsackievirus B1 strains associated with severe disease among young infants in the United States, 2007–2008. Clin Infect Dis. 2009;49(5):e44-51.

    Article  Google Scholar 

  33. Chu PY, Tyan YC, Chen YS, Chen HL, Lu PL, Chen YH, Chen BC, Huang TS, Wang CF, Su HJ, et al. Transmission and demographic dynamics of Coxsackievirus B1. PLoS ONE. 2015;10(6):e0129272.

    Article  Google Scholar 

  34. Zhang T, Du J, Xue Y, Su H, Yang F, Jin Q. Epidemics and frequent recombination within species in outbreaks of human enterovirus B-associated hand, foot and mouth disease in Shandong China in 2010 and 2011. PLoS ONE. 2013;8(6):e67157.

    Article  CAS  Google Scholar 

  35. Ji H, Fan H, Lu PX, Zhang XF, Ai J, Shi C, Huo X, Bao CJ, Shan J, Jin Y. Surveillance for severe hand, foot, and mouth disease from 2009 to 2015 in Jiangsu province: epidemiology, etiology, and disease burden. BMC Infect Dis. 2019;19(1):79.

    Article  Google Scholar 

  36. Guan H, Wang J, Wang C, Yang M, Liu L, Yang G, Ma X. Etiology of multiple non-EV71 and non-CVA16 enteroviruses associated with hand, foot and mouth disease in Jinan, China, 2009–June 2013. PLoS ONE. 2015;10(11):e0142733.

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the participating patients and the staff of the Institute of Medical Biology, Chinese Academy of Medical Sciences for their cooperation.

Funding

This work was supported by the Research Projects of Yunnan Province, China (Grant Numbers: 20200AA100009 and 202202AA100016) and Innovation Team Project of Yunnan Science and Technology Department (Grant Numbers: 202105AE160020).

Author information

Authors and Affiliations

  1. Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College (CAMS & PUMC), 935 Jiao Ling Road, Kunming, 650118, Yunnan Province, People’s Republic of China

    Wei Guo, Danhan Xu, Shanri Cong, Ming Zhang, Changzeng Feng, Hao Sun, Zhaoqing Yang & Shaohui Ma

  2. Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Kunming, 650118, People’s Republic of China

    Wei Guo, Danhan Xu, Shanri Cong, Ming Zhang, Changzeng Feng, Hao Sun, Zhaoqing Yang & Shaohui Ma

  3. Department of Infectious Diseases, Kunming Children’s Hospital, Kunming, China

    Zengqing Du

  4. Department of Clinical Laboratory, Kunming Maternal and Child Health Hospital, Kunming, 650031, China

    Li Li

  5. First People’s Hospital of Yunnan Province, Kunming, 650032, People’s Republic of China

    Guohong Bao

Authors
  1. Wei Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Danhan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shanri Cong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zengqing Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Li Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ming Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Changzeng Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Guohong Bao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hao Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Zhaoqing Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Shaohui Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

GW, XDH, and CSR contributed equally to this article. GW, XDH and CSR wrote the manuscript. ZM, FCZ, MSH and SH, YZQ were involved in the correction and editing of the draft. DZQ, LL and BGH were involved in the clinical management of patients and data collection. All authors have read and approved the final manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Shaohui Ma.

Ethics declarations

Ethics approval and consent to participate

This study was conducted at the Chinese Academy of Medical Sciences and was approved by the Ethics Committee of the Chinese Academy of Medical Sciences. Each patient had written informed consent, and for some of the patient samples in this study were from minors under 16 years of age, informed consent was obtained from their parents or legal guardians to participate in this study. All investigations and methods were conducted in accordance with the guidelines and regulations of the Chinese Academy of Medical Sciences.

Consent for publication

Not applicable.

Competing interests

The authors declare they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, W., Xu, D., Cong, S. et al. Co-infection and enterovirus B: post EV-A71 mass vaccination scenario in China. BMC Infect Dis 22, 671 (2022). https://doi.org/10.1186/s12879-022-07661-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12879-022-07661-3

Keywords

BMC Infectious Diseases

ISSN: 1471-2334

Contact us